Imène Hadji: Where is Cancer Immunotherapy Heading?
Imène Hadji/LinkedIn and Paulino Tallón de Lara/faculty.mdanderson.org

Imène Hadji: Where is Cancer Immunotherapy Heading?

Imène Hadji, Medical Oncologist at CHU Annaba, shared on LinkedIn:

“JIPO at ESMO26: where is cancer immunotherapy heading? With Dr. Paulino Tallón de Lara.

It was a pleasure to speak with Dr. Paulino Tallón de Lara (UT MD Anderson), at ESMO 2026 about the future of immuno-oncology.

Highlights from our conversation:

  • Where immunotherapy is heading: ESMO 2026 brought a lot of data on cancer vaccines and on bispecific and trispecific antibodies, which Dr. Tallón de Lara sees as the two dominant approaches.
  • A result that stood out: the early data for CS2009, a PD-1/CTLA-4/VEGF trispecific antibody used alone in microsatellite-stable (MSS) colorectal cancer.
  • Unanswered questions: what do non-conventional T cells do? What about innate lymphoid cells and myeloid cells? We have too few agents against them, because we still don’t know their biology well enough.
  • Early drug development: the most important approach is knowing more biology.
  • Biomarkers: if we understand the biology, we can predict response. MSI-high in colorectal cancer is a good example, and it is also why MSS and MSI-high behave like two different diseases.
  • A message to young oncologists: ‘silences are part of music.’ Rest, exercise and hobbies are not a distraction from great work, because original ideas come more easily when you are happy and rested.

Thank you, Dr. Tallón de Lara, for your time, your generosity and your honesty.

Watch the full interview.”

You can also read:

Beyond MSI Status: A New Biomarker of Immunotherapy Resistance in Colorectal Cancer

OncoDaily

10 Must-Read Posts in Immuno-Oncology This Week

OncoDaily